CenTrial Logo

Revolutionary New Drug Tirzepatide Shows Promising Results in Reducing Obesity


Clinical trial shows tirzepatide effective for weight loss

Obesity is a condition in which excess body fat can lead to various health problems, including heart disease, stroke, type 2 diabetes, certain cancers, and sleep apnea. In addition to physical health problems, obesity can also lead to mental health problems, such as depression and anxiety.

Obesity treatment typically involves lifestyle changes, such as increased physical activity and improved diet, and medical interventions, such as weight loss medication or bariatric surgery. However, long-term weight loss can be challenging, and many struggle to maintain weight loss over time. There is an urgent need for safe and effective treatments to help people with obesity achieve and maintain weight loss.

In a clinical trial, researchers investigated the efficacy and safety of a novel medication, tirzepatide, in adults with obesity. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, reduces glucagon secretion, and suppresses appetite. GIP and GLP-1 are called ‘incretin’ hormones, which play crucial roles in regulating metabolism. Tirzepatide is approved for treating type 2 diabetes in the USA, Europe, and the UAE.

The study was a double-blind, randomized, controlled trial that involved 2,539 adults with a body-mass index of 30 or more or 27 or more and at least one weight-related complication, excluding diabetes. Participants were randomly assigned to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or a placebo for 72 weeks, including a 20-week dose-escalation period.

Dose escalation is a process in which a medication is gradually increased in dosage over time to minimize the risk of side effects and maximize the therapeutic benefit. It is a common practice in clinical trials to ensure medication's safe and effective use.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
Tirzepatide treatment resulted in significant weight loss compared to the placebo. The mean percentage change in weight at week 72 was -15.0% with a 5-mg weekly dose of tirzepatide, -19.5% with a 10-mg dose, and -20.9% with a 15-mg dose, compared to -3.1% with placebo.

The percentage of participants who had a weight reduction of 5% or more was also significantly higher in the tirzepatide groups (85%, 89%, and 91%) compared to the placebo group (35%). Furthermore, 50% and 57% of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, respectively, compared to only 3% in the placebo group.

The study also found improvements in all prespecified cardiometabolic measures with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in a small percentage of participants in each group.

In conclusion, this 72-week trial showed that once-weekly tirzepatide treatment provided substantial and sustained reductions in body weight in adults with obesity. The study's findings suggest that tirzepatide could be a safe and effective treatment option for people with obesity. However, further research is needed to confirm these results and assess long-term safety and efficacy.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Whether you're healthy or have a medical condition you can participate in a clinical trial.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.